Journal Logo

Original Basic Science—General

C1-Inhibitor Treatment Decreases Renal Injury in an Established Brain-Dead Rat Model

Poppelaars, Felix BSc1; Jager, Neeltina M. BSc2; Kotimaa, Juha PhD3,4; Leuvenink, Henri G.D. PhD2; Daha, Mohamed R. PhD1,3; van Kooten, Cees PhD3; Seelen, Marc A. MD, PhD1; Damman, Jeffrey MD, PhD5

Author Information
doi: 10.1097/TP.0000000000001895

Today, brain-dead (BD) donors still comprise most deceased organ donors. It is well known that fully mismatched living donors have better early graft function and improved long-term outcome compared with kidneys from fully matched deceased donors.1 This illustrates that donor origin is an important cause of allograft injury. Donor brain death is characterized by hemodynamic and hormonal instabilities resulting in immune activation and eventually decreased organ viability before and after transplantation.2,3 Therefore, attenuating BD-induced renal injury in the donor seems to be a promising therapeutic strategy to improve outcome after renal transplantation.3,4

The harmful effect of donor brain death on renal allograft survival is in part explained by immunological changes.5,6 BD donors have increased levels of cytokines (IL-1β, IL-6, IL-8), chemokines (MCP-1), and adhesion molecules (ICAM-1, vascular cell adhesion molecule 1 [VCAM-1], E- and P selectin).7 Subsequently, increased numbers of infiltrating macrophages (MФ) and polymorphonuclear (PMN) cells are found in renal tissue of BD donors.8,9 Ultimately, this leads to tissue damage and repair as reflected by increased expression of kidney injury marker 1 (KIM-1), a marker of BD-induced renal injury.10 Consequently, recipients of renal allografts from BD donors have a higher chance to develop delayed graft function (DGF, defined as the need for dialysis within the first 7 days posttransplant) and a lower long-term renal graft survival.1,11

There is circumstantial evidence for a prominent role of complement activation in the pathogenesis of renal injury in deceased donors.12 In previous studies we demonstrated that circulating complement components are activated in deceased donors and are associated with acute rejection after renal transplantation.13 Furthermore, in kidneys from BD donors, complement component 3 (C3) was upregulated and activated before kidney retrieval without additional expression after cold ischemia or reperfusion.14 Moreover, microarray analysis of 554 kidney biopsies showed enrichment of complement pathways in BD donors before organ retrieval.15 In addition, genetic variation of donor C3 was associated with allograft outcome of deceased donors.16,17 Altogether, these data demonstrate that complement activation plays a pivotal role in BD-associated renal injury and may impact long term allograft survival rates. In accordance with this, inhibition of the complement system in rat BD donors was shown to improve renal allograft function in the recipient after transplantation.18

C1 esterase inhibitor (C1-INH) is one of the central regulators of the complement system, as it interacts with different complement factors and additionally plays a key role in the kinin and coagulation system.19 Previously, it has been shown that C1-INH is able to inhibit complement activation in vitro of the classical pathway (CP), the lectin pathway (LP) and the alternative pathway (AP).20-22 The clinical value of C1-INH has been well established because it has been used extensively for the prophylaxis and treatment of hereditary angioedema.23 Preliminary clinical studies in transplantation show the therapeutic potential of C1-INH in the treatment of renal ischemia-reperfusion injury and antibody-mediated rejection.24

The aim of our study was to investigate the effect of C1-INH on BD-induced renal injury. Rats were treated after the induction of brain death, because it is analogous to a potential clinical intervention strategy that would involve treating human BD donors before procurement for transplantation.



Adult male Fisher F344 rats (260-300 g) were used. Animals received care in compliance with the guidelines of the local animal ethics committee per Experiments on Animals Act (1996) issued by the Dutch Ministry of Public Health, Welfare and Sports.

Experimental Protocol

Nanofiltered plasma derived C1-inhibitor (Cinryze) was provided by ViroPharma, Exton, USA. Brain death was induced as described previously.25 In short: animals were anesthetized, intubated and ventilated. A baseline blood sample (100 μL) was drawn. Temperature and blood pressure were continuously monitored and regulated. Through a frontolateral borehole in the skull, a catheter was placed subdural and inflated slowly. The induction was completed after 30 minutes and the rats were brain dead. After another 30 minutes, a blood sample (100 μL) was taken (before treatment). During brain death, animals received no anesthesia. If blood pressure fell below 80 mm Hg, it was restored by the administration of 500 μL of 10% hydroxyethyl starch solution or 0.01 mg/mL of noradrenaline (Table S1, SDC, After 4 hours of brain death, blood was collected from the aorta and organs were flushed with cold saline and retrieved. Retrieved organs were paraffin embedded or snap frozen in liquid nitrogen stored at −80°C together with collected serum. In the sham-operated group, a hole was drilled in the skull without insertion of the balloon catheter and animals were ventilated for half an hour under anesthesia before animals were sacrificed (Figure 1). Rats were randomly divided into 6 groups:

Schematic presentation of the protocol in BD rats and sham-operated rats. In the BD group, a catheter was placed subdural through a frontolateral borehole in the skull and inflated slowly. After 30 minutes, rats were brain death another 30 minutes later BD rats were treated with saline, a low-dose of C1-INH (100 U/kg) or a high-dose of C1-INH (400 U/kg). After 4 hours of brain death, animals were sacrificed and organs were collected. Blood samples were collected at baseline, 30 minutes after BD (before intervention) and after 4 hours of BD. In the sham group, a hole was drilled in the skull without insertion of the balloon catheter and animals were ventilated for half an hour under anesthesia before animals were sacrificed. Directly after sham surgery rats were treated with saline, low-dose or high-dose of C1-INH. Blood samples were collected at baseline (before intervention) and 30 minutes after sham surgery.
  • Group 1: sham-operated rats (n = 4) treated with saline.
  • Group 2: sham-operated rats (n = 4) treated with a 100 U/kg of C1-INH (=low-dose).
  • Group 3: sham-operated rats (n = 4) treated with 400 U/kg of C1-INH (=high-dose).
  • Group 4: BD rats (n = 10) treated with saline.
  • Group 5: BD rats (n = 10) treated with 100 U/kg of C1-INH (=low-dose), 0.5 hour after BD.
  • Group 6: BD rats (n = 10) treated with 400 U/kg of C1-INH (=high-dose), 0.5 hour after BD.

All treatments were administered via the femoral vein and the volume of the treatment (500 μL) was equal between the different groups. After the confirmation of BD, the mean arterial pressure was kept above 80 mm Hg in all animals throughout the experiment (Figure S1, SDC,

RNA Isolation and qPCR

Total RNA was extracted from rat kidneys using the TrIzol reagent method (Invitrogen, Breda, the Netherlands). The isolated RNA was then treated with DNAse I to remove any contamination with genomic DNA (Invitrogen, Breda, the Netherlands). The integrity of isolated RNA was analyzed by using gel electrophoresis. Complementary DNA (cDNA) was synthesized from 1-μg total RNA using the Moloney murine leukemia virus Reverse Transcriptase enzyme kit (Invitrogen), oligo dT primers and RNase inhibitor (Invitrogen, Breda, The Netherlands) according to the manufacturer’s protocol. Primer sequences (Table 1) were designed based on Primer Express 2.0 software (Applied Biosystems, Foster City, CA). Amplification and detection were performed with the ABI Prism 7900-HT Sequence Detection System (Applied Biosystems) using emission from SYBR green master mix (Applied Biosystems). All samples for RT-PCR were done in triplicate. The expression of genes was normalized to β actin. The data are presented as fold increase compared with the housekeeping gene. Fold increase of the sham-operated rats treated with saline was set at 1; the other groups were calculated accordingly.

Gene-specific qPCR primers and their respective PCR fragment lengths


Frozen sections were fixed with acetone, followed by endogenous peroxidase blocking. Paraffin embedded tissue sections were deparaffinized and antigen retrieval was performed, followed by endogenous peroxidase blocking. Sections were incubated with a primary antibody for 1 hour at RT (Table 2). After washing, sections were incubated with appropriate secondary and tertiary antibodies (Dako, Glostrup, Denmark). The reaction was developed by the addition of 3-amino-9-ethylcarbazole and counterstained with hematoxylin solution (Merck, Darmstadt, Germany).

Primary antibodies used for Immunohistochemistry

For HIS48 and ED-1 (for granulocytes and macrophages, respectively), in each section, the number of glomerular and interstitial positive cells was assessed as the average count from 20 different microscopic fields, randomly divided throughout the renal cortex, using a light microscope (objective, 200×).

Biochemical Determinations

Creatinine and lactate dehydrogenase (LDH) were determined in serum samples in a routine fashion (Mega, Merck, Amsterdam, The Netherlands).

Complement Activation and Functional Levels

Rat complement pathway activity was assessed by functional complement ELISAs for the CP, LP and AP. The sC5b-9 ELISA was used for the detection of complement activation.26 Per rat the baseline values were set at a 100% or 1 AU/mL and consecutive samples were calculated accordingly.


IL-6 production in serum was determined using Rat IL-6 Quantikine ELISA Kit (R&D Systems, Abingdon, UK) per the supplied protocol.


Statistical analysis was performed with StatsDirect (v 3.0.133, Cheshire, UK). The Kruskal-Wallis test and Mann-Whitney U test were used to assess differences between groups of nonparametric data and 1-way analysis of variance and t test for normally distributed data. The Dwass-Steel-Critchlow-Fligner test was then used to determine where the differences lay. All statistical tests were 2-tailed with P less than 0.05 regarded as significant. Results are presented as a median and interquartile range for nonparametric data and mean and SEM for parametric data.


Treatment With C1-INH Protects Kidneys From Brain Death-Induced Injury

In BD rats, creatinine levels were significantly higher after 4 hours compared with sham-operated animals, indicating reduced renal function (Figure 2A, P < 0.001). In accordance with these observations, renal mRNA expression of KIM-1 was also significantly upregulated in kidneys from BD rats compared with controls (Figure 2B, P < 0.001). Because complement is known to play a role in BD-induced renal injury, we investigated the effect of C1-INH treatment on kidneys of BD donors. High-dose C1-INH treatment significantly reduced creatinine levels (Figure 2A). Median creatinine levels in BD rats treated with high-dose C1-INH were 64 μM, compared with 96 μM in saline-treated BD rats (P < 0.01). Sham-operated rats had a median creatinine of 34 μM. In accordance, high-dose C1-INH treatment reduced renal injury in BD rats as seen by the lower mRNA expression of KIM-1 (Figure 2B). KIM-1 expression in BD kidneys was 47% lower in the C1-INH–treated rats compared with untreated rats (P < 0.01). Low-dose C1-INH treatment was unable to improve renal function or injury.

C1-inhibitor treatment in BD rats reduced renal injury. (A) Plasma creatinine levels of BD or sham-operated rats treated with saline, 100 U/kg (low) C1-INH or 400 U/kg (high) C1-INH. (B) KIM-1 gene expression in kidneys of rats after BD or sham operation. Quantitative real-time RT-PCR was performed. The mRNA expression of KIM-1 relative to β actin was set at 1 in sham-operated rats treated with saline and the other values are calculated accordingly. Data are shown as median and interquartile range and were analyzed by Kruskal-Wallis test with an option for multiple comparisons (**P < 0.01, ***P < 0.001). Asterisks above the bars denote significant differences between BD and sham animals of the same treatment, while asterisks above the capped line indicate significant differences between BD groups from the different treatments. The number of rats used is 10 per BD group and 4 per sham-operated group.

Furthermore, BD rats had significantly higher levels of LDH compared with the sham group (P < 0.001). High-dose C1-INH treatment led to significant lower LDH levels compared with the untreated BD rats (Figure 3A, P < 0.05). On the other hand, BD-induced renal apoptosis was not altered by C1-INH treatment because the Bcl2/BAX-ratio was not significantly different between the groups (Figure 3B).

C1-inhibitor treatment reduces tissue damage in BD rats but not renal apoptosis. (A) Plasma LDH levels of BD or sham-operated rats treated with saline, 100 U/kg (low) C1-INH or 400 U/kg (high) C1-INH. (B) BAX/BCl-2 gene expression ratio in kidneys of rats after brain death. Quantitative real-time RT-PCR was performed. The ratio was calculated by dividing BAX mRNA expression by Bcl-2 mRNA expression. Data are shown as median and interquartile range and were analysed by Kruskal-Wallis test with an option for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Asterisks above the bars denote significant differences between BD and sham animals of the same treatment, while asterisks above the capped line indicate significant differences between BD groups from the different treatments. N is 10 for BD groups and N is 4 for sham groups.

Brain Death Leads to Local and Systemic Complement Activation, Resulting in Complement Consumption

Next, we investigated complement activation and functional levels during brain death. The sC5b-9 levels increased significantly during brain death from 1.00 AU/mL at baseline to 1.95 AU/mL after 4 hours (Figure 4A, P < 0.001). Between 0.5 and 4 hours after BD induction the sC5b-9 levels rose as well although not statically significant (0.5 hour, 1.42 AU/mL; 4 hours, 1.95 AU/mL). In sham-operated animals there was no significant increase in sC5b-9 levels (Figure S2A, SDC, Subsequently, we assessed whether treatment with C1-INH was able to prevent systemic complement activation in rats when administered 0.5 hour after BD. High-dose C1-INH treatment prevented further increase between 0.5 and 4 hours in BD rats (0.5 hour, 1.47 AU/mL; 4 hours, 1.53 AU/mL). However, after 4 hours sC5b-9 levels were still significantly higher than baseline samples in the C1-INH–treated BD rats.

C1-inhibitor treatment prevented further complement activation and consumption of the CP and AP, but not the LP. Plasma soluble C5b-9 (sC5b-9) levels (A) and functional complement levels for the CP (B), LP (C) and AP (D) of BD rats. Levels were determined at baseline (t = 0 hour), before treatment (t = 0.5 hour) and before sacrifice (t = 4 hours). Values at baseline are set at 1.0 or 100% per rat, and other consecutive levels are calculated accordingly. Data are expressed as mean percentage ± SEM and analysed by ANOVA with a Bonferroni post hoc test. Significant differences are indicated (*P < 0.05; **P < 0.01 and ***P < 0.001). N is 10 for BD groups; except for the saline-treated BD rats (N = 9).

We next determined whether the systemic complement activation was accompanied by complement depletion by measuring functional complement levels. In BD rats, functional levels were significantly lower after 4 hours compared with baseline levels for all 3 pathways (P < 0.05). After 4 hours, functional levels were 72%, 74% 74% for the CP, LP and AP, respectively (Figures 4B-D). There was a drop in functional levels for all pathways between 0.5 and 4 hours as well, however, this was not significant. In the control group, functional levels of the LP and AP were not significantly altered by the sham-operation (Figure S2CD, SDC, Nonetheless, there was a significant decrease in the functional levels of the CP in the sham-operated animals (15% reduction compared with baseline, P < 0.05). Next, we determined whether treatment with C1-INH prevented complement consumption in rats when administered 0.5 hour after BD induction. For the CP, functional levels rose between 0.5 and 4 hours after both low-dose and high-dose C1-INH treatment (Figure 4B). After 4 hours, functional levels were no longer significantly lower compared with baseline. In the sham-operated rats, high-dose C1-INH significantly increased CP functional complement levels as well (Figure S2B, SDC, For the AP, a similar protection was seen after both low-dose and high-dose C1-INH treatment (Figure 4D). Strikingly, high-dose C1-INH treatment even significantly increased functional AP levels compared with baseline (P < 0.05), indicating prevention of complement consumption of the AP. For the LP, the significant decrease in functional levels by BD could not be prevented by C1-INH (Figure 4C).

C1-INH Treatment Reduces Both Renal IL-6 Expression and Systemic IL-6 Levels

Subsequently, we assessed the gene expression of proinflammatory cytokines (IL-1β, IL-6, and TNF-α), chemokine’s (MCP-1), and adhesion molecules (VCAM-1, ICAM-1, E selectin, and P selectin). In BD rats, renal expression levels of IL-6, MCP-1, VCAM-1, and P selectin were significantly increased compared with sham-operated rats (Figure 5). No significant increase was found for renal expression of IL-1β, TNF-α, E-selectin and ICAM-1 in BD rats (data not shown). Next, we evaluated the effect of C1-INH treatment on the expression of IL-6, MCP-1, VCAM-1, and P selectin. Treatment with both high-dose and low-dose C1-INH significantly reduced VCAM-1 expression (Figure 5A). A clear downward trend was visible for IL-6 expression in the BD rats treated with C1-INH compared with untreated animals (Figure 5B). In BD rats with high-dose C1-INH renal expression of IL-6 was reduced by 55% (P < 0.001). Serum levels of IL-6 were also determined to assess whether systemic levels of IL-6 were also lower in C1-INH–treated animals (Figure 6). Levels of IL-6 were not determined in the sham groups. The median IL-6 serum concentration was 107 pg/mL in high-dose C1-INH–treated rats compared with 206 pg/mL in BD controls (P < 0.05).

Reduction in renal gene expression of inflammatory mediators in BD rats after C1-inhibitor treatment. Gene expression of inflammatory markers in kidneys of BD or sham-operated rats, determined by quantitative real-time RT-PCR. mRNA expression of (A) IL-6, (B) VCAM-1, (C) MCP-1, (D) P selectin. Data are shown as expression relative to β actin, were sham-operated rats treated with saline are set at 1 and the rest is calculated accordingly. Data are shown as median and interquartile range and were analysed by Kruskal-Wallis test with an option for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Asterisks above the bars denote significant differences between BD and sham animals of the same treatment, while asterisks above the capped line indicate significant differences between BD groups from the different treatments. N is 10 for BD groups and N is 4 for sham groups.
C1-inhibitor treatment led to reduced systemic IL-6 in BD rats. Serum levels of IL-6 in BD rats, treated with saline or C1-INH. Data are shown as median and interquartile range and were analysed by Mann-Whitney U test (*P < 0.05). N is 10 per groups.

To further characterize local renal inflammation upon brain death, infiltrating neutrophils (PMN) and macrophages (MΦ) were quantified by immunohistochemistry. There was a significant increase in the number of infiltrating PMN but not in MΦ in the renal cortex of BD rats compared with the sham-operated group (P < 0.01). Treatment with C1-INH, low or high-dose, did not attenuate the increase in infiltrating PMN in the renal cortex (Figure 7A). However, treatment with C1-INH in the BD rats appears to lead to increased number of MΦ compared with BD controls and C1-INH sham-operated rats (Figure 7B).

C1-inhibitor did not decrease the number of infiltrating granulocytes or macrophages in the renal cortex of BD rat. Renal influx of PMN and macrophages (M[Latin Small Letter Turned phi]) was evaluated by immunohistochemistry. The HIS48 monoclonal antibody reacts with a molecule expressed on the surface of all rat granulocytes. The monoclonal antibody ED1 is a marker for rat macrophages. In each section, the number of interstitial positive cells was assessed by the average count from 10 different microscopic fields, randomly divided throughout the renal cortex, using a light microscope (objective, 200×). Data are shown as median and interquartile range and were analysed by Kruskal-Wallis test with an option for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Asterisks above the bars denote significant differences between BD and sham animals of the same treatment, while asterisks above the capped line indicate significant differences between BD groups from the different treatments. N is 10 for BD groups and N is 4 for sham groups.


In this study, we demonstrated that complement inhibition in BD donors attenuates renal injury before organ retrieval. In our model, animals were treated after the induction of brain death, because this closely resembles the potential clinical situation that would involve treating donors after the diagnosis of brain death. We found that high-dose C1-INH treatment after brain death induction decreased local renal and systemic inflammation and renal injury and improved renal function in the donor. Therefore, strategies targeting complement activation in human BD donors might improve donor organ viability and renal allograft survival. The ideal timing to target complement activation would be in the intensive care unit, shortly after confirmation of brain death. Potentially, complement inhibition in the donor could be more effective than in the recipient before reperfusion injury, because complement is already activated in the donor. In humans, randomized clinical trials must explore whether complement inhibition in BD donors alone or in combination with treatment of the recipient would improve renal allograft outcome after kidney transplantation.

Donor organ injury induced by brain death is considered to be an important risk factor for DGF, renal allograft graft rejection and allograft survival after transplantation.1,11,27-29 The complement system has been shown to play an important role in BD-induced renal injury.13,14,30 In addition, treatment with complement inhibiting drugs has proven to be beneficial in preclinical models of DGF,18 emphasizing that strategies targeting complement activation are potentially beneficial in the transplantation setting. C1-INH is a complement inhibitor of all 3 pathways,20-22 and this already-available therapeutic agent is currently used for the treatment of hereditary angioedema. C1-INH treatment has already been shown to improve outcome in a number of disease models, including ischemia-reperfusion injury, antibody-mediated transplant rejection and xenotransplantation models.31 The use of C1-INH may have greater benefits in BD donors than other complement inhibitors. Plasma-derived C1-INH appears to be extremely safe, since it has been used for over 3 decades.32 C1-INH also regulates the coagulation system and can inhibit leukocyte adhesion to the endothelium, which also contributes to BD-induced renal injury.14,15,33 It has been suggested that C1-INH has additional anti-inflammatory functions and antiapoptotic effects independent of protease inhibition.34-36 C1-INH also regulates the coagulation and the kallikrein-kinin systems, which also contributes to BD-induced organ injury.14,15,37 A vital consideration for any intervention in BD donors is that it should not impact the successful utilization of other organs. This is a potential limitation of complement inhibition in the donor, because it is not known if all donor organs would benefit from such therapy. Nevertheless, C1-INH treatment has already shown promising results in lung transplantation.38 In addition to the trials for the treatment of renal ischemia-reperfusion injury and renal antibody-mediated rejection,34,39-42 C1-INH treatment is also being tested in liver transplantation (24, NCT 01886443 and 02251041). In accordance, in our study C1-INH did not negatively impact the liver because specific injury markers, aspartate transaminase and alanine transaminase, were unaltered (Figure S3, SDC, Lastly, C1-INH inhibits at an early point and could thereby decrease organ injury, whereas later blockage can only eliminate effector functions of complement activation.

The cause of the immune activation in BD donors is not well understood but it is thought to be initiated by damage-associated molecular patterns and pathogen-associated molecular patterns in the systemic circulation as well as in the local environment.35 Studies on the contribution of complement in brain death have mostly focused on local C3 expression and synthesis.14,31,36 However, we show that brain death induces systemic complement activation already after 0.5 hour. Between 0.5 and 4 hours of BD, there was a further stepwise increase of sC5b-9. Furthermore, induction of brain death led to significant lower functional levels of all 3 pathways, which reflects significant systemic complement activation. This is in line with findings in human BD donors that showed increased plasma levels of sC5b-9, C4d and Bb.13 In our animal model, significant complement consumption of the CP and AP in BD rats was prevented by treatment with high-dose C1-INH, thereby increasing functional levels of these pathways. No effect of C1-INH treatment could be seen on the LP. However, human C1-INH was used to inhibit complement in rats and the biggest discrepancies among the complement pathways between rodents and humans are found in the LP.43 Altogether, these data show that high-dose C1-INH prevented the further increase of sC5b-9 by BD and thereby increased functional levels of the CP and AP. This excludes the possibility that the in vivo administered C1INH is interfering with the in vitro activity assay. Furthermore, the concentration of C1-INH used here is comparable to previous studies in pigs and human.34,39

Our study shows that renal inflammation is significantly reduced after treatment of BD rats with C1-INH. High-dose C1-INH treatment partly prevented the BD-induced gene expression of IL-6 and VCAM-1. Furthermore, also systemic IL-6 was significantly reduced by C1-INH treatment. These findings suggest that complement inhibition by C1-INH protects allografts from development of inflammation. However, we did not assess systemic levels of TNF-α and IL-1β, because previous studies of this model have shown that IL-6 is the cytokine that is significantly elevated, opposed to other prominent proinflammatory markers such as IL-1β and TNF-α.8 Additionally, IL-6 has been shown to be an important mediator in the proinflammatory reaction of BD.44-47 Recently, it was demonstrated that higher levels of IL-6 in the donor are associated with a worse outcome in the recipient.48 Thus, C1-INH treatment leads to a better renal function in BD donors, which could be ascribed to a consequence of improved organ allograft quality by reducing inflammatory cytokines IL-6.

C1-INH significantly reduced creatinine levels in our BD model before organ retrieval. Yet, creatinine levels remained significantly higher than sham-operated animals. Hemodynamic and hormonal instabilities should also be considered in brain death because these changes additionally affect renal function. KIM-1 expression was also significantly lower by C1-INH treatment. KIM-1 has been shown to be a specific marker of BD-induced kidney damage. In human BD donors, urinary KIM-1 has been shown to be associated with renal function after transplantation.10 In addition, levels of LDH significantly increased during brain death compared with the sham group, indicating progressive cell damage. C1-INH reduced LDH levels, although this could not be explained by changes in renal apoptotic in the mitochondria-mediated (intrinsic) pathway. However, the extrinsic pathway of apoptosis and necrosis was not assessed. Treatment with C1-INH did not prevent the increase in infiltrating PMN in the renal cortex. However, information on the dynamics and time frame of the influx of inflammatory cells is absent, because the influx was only determined 4 hours after BD. Previously, significant PMN infiltration has already observed in rat kidneys, 30 minutes after BD.9 Because C1-INH treatment was administered 30 minutes after BD, this could explain the ineffectiveness on the influx of PMNs. Unexpectedly, C1-INH treatment led to a significant increase in influx of MΦ. However, this increase could be was caused by macrophages that decrease inflammation and encourage tissue repair (called M2 macrophages) rather than macrophages that encourage inflammation (called M1 macrophages).

We acknowledge that the present study has limitations. Firstly, despite the significant protection demonstrated by C1-INH in preserving the kidney in our model, further investigations are necessary to evaluate the effect of C1-INH on BD-induced renal injury in larger animals and/or humans. Secondly, only male rats were used for our experiments. This was due to lack of data on the effect of gender on brain death, as well the reduced ability to activate complement in female rodents.49,50 In addition, in this study human plasma-derived C1-INH was used for the treatment of rodents. Furthermore, it is unlikely that monotherapy with C1-INH in the donor would fully abolish the issue of DGF. We hypothesize that the ideal treatment regime in BD, would be the combination of hormone replacement therapy, improvement of hemodynamic and immunomodulators. C1-INH treatment could be a key component in this triple combination therapy for BD-induced kidney injury. Lastly, the primary outcome measured was renal injury after BD. The effect of donor treatment with C1-INH on posttransplantation outcome therefore remains to be determined. However, donor treatment is expected to positively impact posttransplant outcome.

In conclusion, an important finding of this study is that treatment of the donor with a single dose of C1-INH after the induction of BD protects against BD-induced renal injury. These findings open a new window of opportunity for complement inhibition in BD donors to potentially improve kidney grafts for transplantation.


The authors thank Anita Meter-Arkema, Petra Ottens, Ngaisah Klar-Mohammad and Zwanida Veldhuis for the excellent technical assistance.


1. Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333:333–336.
2. Citerio G, Cypel M, Dobb GJ, et al. Organ donation in adults: a critical care perspective. Intensive Care Med. 2016;42:305–315.
3. Fung A, Zhao H, Yang B, et al. Ischaemic and inflammatory injury in renal graft from brain death donation: an update review. J Anesth. 2016;30:307–316.
4. Bos EM, Leuvenink HG, van Goor H, et al. Kidney grafts from brain dead donors: Inferior quality or opportunity for improvement? Kidney Int. 2007;72:797–805.
5. Westendorp WH, Leuvenink HG, Ploeg RJ. Brain death induced renal injury. Curr Opin Organ Transplant. 2011;16:151–156.
6. Watts RP, Thom O, Fraser JF. Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant. 2013;2013:521369.
7. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant. 2009;9:989–997.
8. Nijboer WN, Schuurs TA, van der Hoeven JA, et al. Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation. 2004;78:978–986.
9. Schuurs TA, Morariu AM, Ottens PJ, et al. Time-dependent changes in donor brain death related processes. Am J Transplant. 2006;6:2903–2911.
10. Nijboer WN, Schuurs TA, Damman J, et al. Kidney injury molecule-1 is an early noninvasive indicator for donor brain death-induced injury prior to kidney transplantation. Am J Transplant. 2009;9:1752–1759.
11. Ounissi M, Cherif M, Abdallah TB, et al. Risk factors and consequences of delayed graft function. Saudi J Kidney Dis Transpl. 2013;24:243–246.
12. Damman J, Schuurs TA, Ploeg RJ, et al. Complement and renal transplantation: from donor to recipient. Transplantation. 2008;85:923–927.
13. Damman J, Seelen MA, Moers C, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011;92:163–169.
14. Damman J, Nijboer WN, Schuurs TA, et al. Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant. 2011;26:2345–2354.
15. Damman J, Bloks VW, Daha MR, et al. Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. Transplantation. 2014;99:1293–1300.
16. Damman J, Daha MR, Leuvenink HG, et al. Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant. 2012;12:660–668.
17. Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med. 2006;354:2014–2023.
18. Damman J, Hoeger S, Boneschansker L, et al. Targeting complement activation in brain-dead donors improves renal function after transplantation. Transpl Immunol. 2011;24:233.
19. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost. 2011;37:362–374.
20. Poppelaars F, Damman J, de Vrij EL, et al. New insight into the effects of heparinoids on complement inhibition by C1-inhibitor. Clin Exp Immunol. 2016;184:378–388.
21. Jiang H, Wagner E, Zhang H, et al. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. 2001;194:1609–1616.
22. Nielsen EW, Waage C, Fure H, et al. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol. 2007;44:1819–1826.
23. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513–522.
24. Berger M, Baldwin WM 3rd, Jordan SC. Potential roles for C1 inhibitor in transplantation. Transplantation. 2016;100:1415–1424.
25. Kolkert JL, 't Hart NA, van Dijk A, et al. The gradual onset brain death model: a relevant model to study organ donation and its consequences on the outcome after transplantation. Lab Anim. 2007;41:363–371.
26. Kotimaa J, van der Pol P, Leijtens S, et al. Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. J Immunol Methods. 2014;412:14–23.
27. Pratschke J, Wilhelm MJ, Kusaka M, et al. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg. 2000;232:263–271.
28. Pratschke J, Wilhelm MJ, Laskowski I, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol. 2001;12:2474–2481.
29. Sánchez-Fructuoso AI, Prats D, Marques M, et al. Does donor brain death influence acute vascular rejection in the kidney transplant? Transplantation. 2004;78:142–146.
30. Sheen JH, Heeger PS. Effects of complement activation on allograft injury. Curr Opin Organ Transplant. 2015;20:468–475.
31. Atkinson C, Varela JC, Tomlinson S. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009;105:1094–1101.
32. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. [email protected] Transfus Apher Sci. 2003;29:247–254.
33. Gasser M, Waaga-Gasser AM, Grimm MW, et al. Selectin blockade plus therapy with low-dose sirolimus and cyclosporin a prevent brain death-induced renal allograft dysfunction. Am J Transplant. 2005;5:662–670.
34. Curci C, Castellano G, Stasi A, et al. Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant. 2014;29:799–808.
35. Poppelaars F, Seelen MA. Complement-mediated inflammation and injury in brain dead organ donors. Mol Immunol. 2016;84:77–83.
36. Rebolledo R, Liu B, Akhtar MZ, et al. Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potential role in complement activation. J Transl Med. 2014;12:111.
37. Davis AE, Cai S, Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology. 2007;212:313–323.
38. Sommer W, Tudorache I, Kühn C, et al. C1-Esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation. 2014;97:1185–1191.
39. Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant. 2016;16:3468–3478.
40. Castellano G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176:1648.
41. Simone S, Rascio F, Castellano G, et al. Complement-dependent NADPH oxidase enzyme activation in renal ischemia/reperfusion injury. Free Radic Biol Med. 2014;74:263–273.
42. Castellano G, Intini A, Stasi A, et al. Complement modulation of anti-aging factor klotho in ischemia/reperfusion injury and delayed graft function. Am J Transplant. 2016;16:325–333.
43. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway—its role in innate immunity and evolution. Immunol Rev. 2004;198:185–202.
44. Murugan R, Venkataraman R, Wahed AS, et al. Preload responsiveness is associated with increased interleukin-6 and lower organ yield from brain-dead donors. Crit Care Med. 2009;37:2387–2393.
45. Pullerits R, Oltean S, Flodén A, et al. Circulating resistin levels are early and significantly increased in deceased brain dead organ donors, correlate with inflammatory cytokine response and remain unaffected by steroid treatment. J Transl Med. 2015;13:201.
46. Saat TC, Susa D, Roest HP, et al. A comparison of inflammatory, cytoprotective and injury gene expression profiles in kidneys from brain death and cardiac death donors. Transplantation. 2014;98:15–21.
47. de Vries DK, Lindeman JH, Ringers J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant. 2011;11:1064–1070.
48. Murugan R, Venkataraman R, Wahed AS, et al. Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation*. Crit Care Med. 2008;36:1810–1816.
49. van der Hoeven JA, Ploeg RJ, Postema F, et al. Induction of organ dysfunction and up-regulation of inflammatory markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors. Transplantation. 1999;68:1884–1890.
50. Kotimaa J, Klar-Mohamad N, Schilders G, et al. Sex matters: systemic complement activity of female C57bl/6 mice is limited by serum terminal pathway components. Mol Immunol. 2016;76:13–21.

Supplemental Digital Content

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.